Clinical characteristics of studied patient cohort
| Demographic and clinical summary | n=63 |
| Age at diagnosis, year | |
| Median | 3.3 |
| Median | 0.5–15.2 |
| Sex (%) | |
| Female | 26 (41.3) |
| Male | 37 (58.7) |
| Race (%) | |
| White | 42 (66.7) |
| African American | 18 (28.6) |
| Other | 3 (4.8) |
| INSS stage (%) | |
| 2B | 1 (1.6) |
| 3 | 7 (11.1) |
| 4 | 55 (87.3) |
| MYCN status (%) | |
| Not amplified | 41 (65.1) |
| Amplified | 21 (33.3) |
| Unknown | 1 (1.6) |
| Shimada histology (%) | |
| Favorable | 5 (7.9) |
| Unfavorable | 40 (69.6) |
| Unknown | 18 (28.6) |
| Survival status (%) | |
| Alive | 56 (88.9) |
| Deceased | 7 (11.1) |
| Autologous transplant (%) | |
| Yes | 57 (90.5) |
| No | 5 (7.9) |
| Unknown | 1 (1.6) |
| Haploidentical NK cell therapy as part of autologous transplant | |
| NK cell donor | |
| Father | 16 (51.6) |
| Mother | 15 (48.4) |
| Infused NK cell dose, ×106/kg median (range) | |
| Median | 20.7 |
| Range | 3.0–114.0 |
| Infused NKT cell dose, ×106/kg | |
| Median | 0.01 |
| Range | 0.00–0.10 |
| Infused T cell dose, ×106/kg | |
| Median | 0.00 |
| Range | 0.00–0.01 |
| Donor KIR—patient HLA mismatch (%) | |
| Yes | 17 (54.8) |
| No | 14 (45.2) |
| Donor KIR mismatch against (%) | |
| KIR2DL1 | 13 (41.9) |
| KIR2DL2/3 | 1 (3.2) |
| KIR3DL1 | 8 (25.8) |
| Autologous HLA–KIR mismatch (%) | |
| Yes | 16 (51.6) |
| No | 15 (48.4) |
| NK cell chimerism on day 7 after infusion | |
| No patients | 22 |
| Median (% donor) | 5 |
| Range | 0.0–81.0 |
| NK cell chimerism on day 21 after infusion | |
| No patients | 26 |
| Median (% donor) | 0.0 |
| Range | 0.0–35.0 |
HLA, human leukocyte antigen; INSS, International Neuroblastoma Staging System; KIR, killer immunoglobulin-like receptor; NK, natural killer.